Roche Combo Shows PFS Gain in Advanced Breast Cancer Trial

Roche announced that Phase III evERA trial data showed giredestrant in combination with everolimus significantly improved progression-free survival (PFS) compared to standard endocrine therapy plus everolimus in patients with ER+ advanced breast cancer. The US FDA has accepted a New Drug Application (NDA) for the combination, with a decision expected by December 18, 2026.